Lv12
20 积分 2024-01-04 加入
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
2小时前
待确认
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2小时前
已完结
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
1天前
已完结
Development of bispecific antibodies in China: overview and prospects
1个月前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers
1个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
3个月前
已完结
Fibrosis in the peritoneum induced by Scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination
3个月前
已完结
Adhesion molecules and TGF-β1 are involved in the peritoneal dissemination of NUGC-4 human gastric cancer cells
3个月前
已完结
Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis
3个月前
已完结
皖公网安备34019202002308
